Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2011, Article ID 312346, 8 pages
http://dx.doi.org/10.4061/2011/312346
Review Article

From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer

1Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA
2Section of Cell and Molecular Biology, The Institute of Cancer Research, London SW3 6JB, UK
33rd Department of Medicine, University of Athens Medical School, 11527 Athens, Greece

Received 11 January 2011; Revised 9 May 2011; Accepted 14 June 2011

Academic Editor: Elizabeth Wiley

Copyright © 2011 Anastasios Dimou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  2. O. Abe, R. Abe, K. Enomoto et al., “Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group,” The Lancet, vol. 351, no. 9114, pp. 1451–1467, 1998. View at Publisher · View at Google Scholar
  3. M. H. Cohen, S. Hirschfeld, S. F. Honig et al., “Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene,” Oncologist, vol. 6, no. 1, pp. 4–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Graziano, “HER-2 breast assay, linked to herceptin, wins FDA's okay,” CAP Today, vol. 12, no. 10, pp. 14–16, 1998. View at Google Scholar · View at Scopus
  5. E. van Cutsem, C. H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Papadopoulos, K. W. Kinzler, and B. Vogelstein, “The role of companion diagnostics in the development and use of mutation-targeted cancer therapies,” Nature Biotechnology, vol. 24, no. 8, pp. 985–995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. V. Scagliotti, G. Selvaggi, S. Novello, and F. R. Hirsch, “The biology of epidermal growth factor receptor in lung cancer,” Clinical Cancer Research, vol. 10, no. 12, pp. 4227s–4232s, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Pao, V. Miller, M. Zakowski et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13306–13311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Rosell, T. Moran, C. Queralt et al., “Screening for epidermal growth factor receptor mutations in lung cancer,” The New England Journal of Medicine, vol. 361, no. 10, pp. 958–967, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Brevet, M. Arcila, and M. Ladanyi, “Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR,” Journal of Molecular Diagnostics, vol. 12, no. 2, pp. 169–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Mitsudomi, S. Morita, Y. Yatabe et al., “Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,” The Lancet Oncology, vol. 11, no. 2, pp. 121–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Pirker, F. J. F. Herth, K. M. Kerr et al., “Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1706–1713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. T. John, G. Liu, and M. S. Tsao, “Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors,” Oncogene, vol. 28, supplement 1, pp. S14–S23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Yu, S. Kane, J. Wu et al., “Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer,” Clinical Cancer Research, vol. 15, no. 9, pp. 3023–3028, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Soh, S. Toyooka, K. Aoe et al., “Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer,” International Journal of Cancer, vol. 119, no. 10, pp. 2353–2358, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Tanaka, Y. Nagai, H. Miyazawa et al., “Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers,” Cancer Science, vol. 98, no. 2, pp. 246–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Kawada, K. Soejima, H. Watanabe et al., “An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients,” Journal of Thoracic Oncology, vol. 3, no. 10, pp. 1096–1103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. M. Heideman, F. B. Thunnissen, M. Doeleman et al., “A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes,” Cellular Oncology, vol. 31, no. 5, pp. 329–333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Nagai, H. Miyazawa, Huqun et al., “Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp,” Cancer Research, vol. 65, no. 16, pp. 7276–7282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Ellison, E. Donald, G. McWalter et al., “A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Park, A. J. Holmes-Tisch, E. Y. Cho et al., “Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 7, pp. 809–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, and M. Filipits, “EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases,” Clinical Cancer Research, vol. 15, no. 14, pp. 4554–4560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. X. Jiang, K. Yamashita, M. Yamamoto et al., “EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance,” International Journal of Cancer, vol. 123, no. 11, pp. 2480–2486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Kitamura, W. Hosoda, E. Sasaki, T. Mitsudomi, and Y. Yatabe, “Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer,” Clinical Cancer Research, vol. 16, no. 13, pp. 3349–3355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Kawahara, C. Yamamoto, K. Nakashima et al., “Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis,” Clinical Cancer Research, vol. 16, no. 12, pp. 3163–3170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Kato, N. Peled, M. W. Wynes et al., “Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1551–1558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, p. e73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Kosaka, Y. Yatabe, H. Endoh et al., “Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib,” Clinical Cancer Research, vol. 12, no. 19, pp. 5764–5769, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Bean, C. Brennan, J. Y. Shih et al., “MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20932–20937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. B. Turke, K. Zejnullahu, Y. L. Wu et al., “Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC,” Cancer Cell, vol. 17, no. 1, pp. 77–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Maheswaran, L. V. Sequist, S. Nagrath et al., “Detection of mutations in EGFR in circulating lung-cancer cells,” The New England Journal of Medicine, vol. 359, no. 4, pp. 366–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. Yao, S. Fenoglio, D. C. Gao et al., “TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15535–15540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. K. E. Ware, M. E. Marshall, L. R. Heasley et al., “Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression,” PloS ONE, vol. 5, no. 11, Article ID e14117, 2010. View at Google Scholar
  40. C. Yamamoto, Y. Basaki, A. Kawahara et al., “Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations,” Cancer Research, vol. 70, no. 21, pp. 8715–8725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Zhou, D. Ercan, L. Chen et al., “Novel mutant-selective EGFR kinase inhibitors against EGFR T790M,” Nature, vol. 462, no. 7276, pp. 1070–1074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Matsubara, S. Ishikawa, S. Oguni, H. Aburatani, M. Fukayama, and T. Niki, “Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells,” Journal of Thoracic Oncology, vol. 5, no. 9, pp. 1317–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Mao, L. X. Qiu, R. Y. Liao et al., “KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies,” Lung Cancer, vol. 69, no. 3, pp. 272–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. R. K. Thomas, A. C. Baker, R. M. Debiasi et al., “High-throughput oncogene mutation profiling in human cancer,” Nature Genetics, vol. 39, no. 3, pp. 347–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. P. D'Angelo, B. Park, C. G. Azzoli et al., “Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center,” Journal of Thoracic and Cardiovascular Surgery, vol. 141, no. 2, pp. 476–480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Ding, G. Getz, D. A. Wheeler et al., “Somatic mutations affect key pathways in lung adenocarcinoma,” Nature, vol. 455, no. 7216, pp. 1069–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Shigematsu, T. Takahashi, M. Nomura et al., “Somatic mutations of the HER2 kinase domain in lung adenocarcinomas,” Cancer Research, vol. 65, no. 5, pp. 1642–1646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. Brose, P. Volpe, M. Feldman et al., “BRAF and RAS mutations in human lung cancer and melanoma,” Cancer Research, vol. 62, no. 23, pp. 6997–7000, 2002. View at Google Scholar · View at Scopus
  49. Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Yamamoto, H. Shigematsu, M. Nomura et al., “PIK3CA mutations and copy number gains in human lung cancers,” Cancer Research, vol. 68, no. 17, pp. 6913–6921, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Dias-Santagata, S. Akhavanfard, S. S. David et al., “Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine,” EMBO Molecular Medicine, vol. 2, no. 5, pp. 146–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. H. I. Ou and J. A. Zell, “Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies,” Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1202–1211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. G. E. Stoica, A. Kuo, A. Aigner et al., “Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin,” Journal of Biological Chemistry, vol. 276, no. 20, pp. 16772–16779, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. H. H. Lee, A. Norris, J. B. Weiss, and M. Frasch, “Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers,” Nature, vol. 425, no. 6957, pp. 507–512, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. C. A. Griffin, A. L. Hawkins, C. Dvorak, C. Henkle, T. Ellingham, and E. J. Perlman, “Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors,” Cancer Research, vol. 59, no. 12, pp. 2776–2780, 1999. View at Google Scholar · View at Scopus
  56. M. Soda, Y. L. Choi, M. Enomoto et al., “Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,” Nature, vol. 448, no. 7153, pp. 561–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Rikova, A. Guo, Q. Zeng et al., “Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer,” Cell, vol. 131, no. 6, pp. 1190–1203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. L. Choi, K. Takeuchi, M. Soda et al., “Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer,” Cancer Research, vol. 68, no. 13, pp. 4971–4976, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson et al., “Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4247–4253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Zhang, S. Zhang, X. Yang et al., “Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression,” Molecular Cancer, vol. 9, article no. 188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. M. Boland, S. Erdogan, G. Vasmatzis et al., “Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas,” Human Pathology, vol. 40, no. 8, pp. 1152–1158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Solomon, M. Varella-Garcia, and D. R. Camidge, “ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 12, pp. 1450–1454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Perner, P. L. Wagner, F. Demichelis et al., “EML4-ALK fusion lung cancer: a rare acquired event,” Neoplasia, vol. 10, no. 3, pp. 298–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Salido, L. Pijuan, L. Martínez-Avilés et al., “Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 21–27, 2011. View at Publisher · View at Google Scholar
  65. M. Soda, S. Takada, K. Takeuchi et al., “A mouse model for EML4-ALK-positive lung cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19893–19897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Sakairi, T. Nakajima, K. Yasufuku et al., “EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration,” Clinical Cancer Research, vol. 16, no. 20, pp. 4938–4945, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. M. P. Martelli, G. Sozzi, L. Hernandez et al., “EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues,” American Journal of Pathology, vol. 174, no. 2, pp. 661–670, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Mino-Kenudson, L. R. Chirieac, K. Law et al., “A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry,” Clinical Cancer Research, vol. 16, no. 5, pp. 1561–1571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Takeuchi, Y. L. Choi, Y. Togashi et al., “KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry- based diagnostic system for ALK-positive lung cancer,” Clinical Cancer Research, vol. 15, no. 9, pp. 3143–3149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. V. K. Anagnostou, A. W. Welsh, J. M. Giltnane et al., “Analytic variability in immunohistochemistry biomarker studies,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 4, pp. 982–991, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Bordeaux, A. W. Welsh, S. Agarwal et al., “Antibody validation,” BioTechniques, vol. 48, no. 3, pp. 197–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. D. R. Camidge, S. A. Kono, A. Flacco et al., “Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment,” Clinical Cancer Research, vol. 16, no. 22, pp. 5581–5590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. M. H. Cohen, R. Justice, and R. Pazdur, “Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer,” Oncologist, vol. 14, no. 9, pp. 930–935, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. H. Cohen, P. Cortazar, R. Justice, and R. Pazdur, “Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC),” Oncologist, vol. 15, no. 12, pp. 1352–1358, 2010. View at Publisher · View at Google Scholar
  76. M. H. Cohen, J. Gootenberg, P. Keegan, and R. Pazdur, “FDA drug approval summary: bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer,” Oncologist, vol. 12, no. 6, pp. 713–718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. S. L. Edwards, C. Roberts, M. E. McKean, J. S. Cockburn, R. R. Jeffrey, and K. M. Kerr, “Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category,” Journal of Clinical Pathology, vol. 53, no. 7, pp. 537–540, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. W. D. Travis, E. Brambilla, M. Noguchi et al., “International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma,” Journal of Thoracic Oncology, vol. 6, no. 2, pp. 244–285, 2011. View at Publisher · View at Google Scholar
  79. R. W. Field, B. J. Smith, C. E. Platz et al., “Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review,” Journal of the National Cancer Institute, vol. 96, no. 14, pp. 1105–1107, 2004. View at Google Scholar · View at Scopus
  80. P. S. Loo, S. C. Thomas, M. C. Nicolson, M. N. Fyfe, and K. M. Kerr, “Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens,” Journal of Thoracic Oncology, vol. 5, no. 4, pp. 442–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Z. Ring, R. S. Seitz, R. A. Beck et al., “A novel five-antibody immunohistochemical test for subclassification of lung carcinoma,” Modern Pathology, vol. 22, no. 8, pp. 1032–1043, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Aharonov, D. Lebanony, H. Benjamin et al., “Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2030–2037, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. J. A. Bishop, H. Benjamin, H. Cholakh, A. Chajut, D. P. Clark, and W. H. Westra, “Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach,” Clinical Cancer Research, vol. 16, no. 2, pp. 610–619, 2010. View at Publisher · View at Google Scholar · View at Scopus